Literature DB >> 1836312

Vasopressin (V1) receptor characteristics in rat aortic smooth muscle cells.

V Gopalakrishnan1, Y J Xu, P V Sulakhe, C R Triggle, J R McNeill.   

Abstract

We report saturable, high-affinity, specific, reversible binding sites for both [3H]arginine vasopressin ([3H]AVP) and d(CH2)5Tyr(Me)-[3H]AVP, a V1-selective antagonist, in cultured smooth muscle cells obtained from rat aorta (RA) and rat mesenteric artery (RMA). Specific binding of [3H]AVP had the following characteristics in adherent monolayers of RA and RMA smooth muscle cells: dissociation constant (KD) = 1.42 and 1.23 nM and maximal binding capacity (Bmax) = 9,500 and 29,910 sites/cell, respectively. Lower KD and higher Bmax values were detected for 3H-labeled V1 antagonist binding to both types of cells. Complete dissociation of [3H]-AVP binding to RA cells occurred in a biphasic manner with two rate constants of dissociation, suggesting high- and low-affinity states of the binding site for the agonist interaction. Partial dissociation of the antagonist-specific binding occurred, and it was monophasic, suggesting interaction of the 3H-labeled V1 antagonist radioligand to the high-affinity binding state. Inhibition constant (Ki) values determined by competitive inhibition of [3H]AVP binding to RA cells by a series of AVP-related peptide analogues and antagonists were consistent with the saturation data. AVP in a concentration-dependent manner induced the accumulation of inositol phosphates [mean effective concentration (EC50) 1 nM] in the adherent RA cells. The free cytosolic Ca2+ level in the dispersed RA smooth muscle cells was increased by AVP (EC50 8.1 nM). Pretreatment with the V1 antagonist abolished these AVP-evoked responses. The data support the conclusion that the agonist binding occurs at a homogeneous population of V1-subtype receptors in the high-affinity (KD = approximately 1 nM) state and that these receptors are functionally coupled to phospholipase C.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1836312     DOI: 10.1152/ajpheart.1991.261.6.H1927

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Fura-2 fluorescent technique for the assessment of Ca2+ homeostasis in cardiomyocytes.

Authors:  Y J Xu; Q Shao; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

2.  Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction.

Authors:  Anyue Yin; Akihiro Yamada; Wiro B Stam; Johan G C van Hasselt; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2018-07-10       Impact factor: 8.739

3.  Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes.

Authors:  Y Xu; R L Hopfner; J R McNeill; V Gopalakrishnan
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

4.  V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.

Authors:  L Gouzénes; N Sabatier; P Richard; F C Moos; G Dayanithi
Journal:  J Physiol       Date:  1999-06-15       Impact factor: 5.182

5.  Limitations of the radioreceptor assay of inositol 1,4,5-trisphosphate in vanadate-treated cell suspensions.

Authors:  L Sandirasegarane; V Gopalakrishnan
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

6.  Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide.

Authors:  A L García-Villalón; J L Garcia; N Fernández; L Monge; B Gómez; G Diéguez
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

7.  Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium.

Authors:  A Jovanović; L Grbović; I Zikić; I Tulic
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.